Cantor Fitzgerald reiterated their buy rating on shares of Aquinox Pharmaceuticals, Inc. (NASDAQ:AQXP) in a report released on Thursday morning. Cantor Fitzgerald currently has a $28.00 price objective on the stock.

“FDA advisory committee meeting could shed light on FDA views of IC/BPS. On December 7, the FDA will hold an advisory panel (details here) to discuss appropriate patient selection criteria and clinical trial design features, including acceptable endpoints, for demonstrating clinical benefit for drugs” to treat the condition. We believe the meeting could be important to raise awareness of the condition and establish expectations for how IC/BPS drugs should be developed.”,” Cantor Fitzgerald’s analyst commented.

Other analysts have also issued reports about the stock. Zacks Investment Research lowered shares of Aquinox Pharmaceuticals from a buy rating to a hold rating in a research note on Tuesday, August 15th. Canaccord Genuity set a $22.00 target price on shares of Aquinox Pharmaceuticals and gave the company a buy rating in a research note on Tuesday, August 8th. BidaskClub raised shares of Aquinox Pharmaceuticals from a sell rating to a hold rating in a research note on Friday, August 4th. Finally, ValuEngine lowered shares of Aquinox Pharmaceuticals from a hold rating to a sell rating in a research note on Friday, September 15th. Two analysts have rated the stock with a sell rating, one has issued a hold rating and three have given a buy rating to the company. The company has an average rating of Hold and an average price target of $22.50.

Aquinox Pharmaceuticals (NASDAQ AQXP) traded up $0.03 during mid-day trading on Thursday, reaching $10.88. 45,900 shares of the company traded hands, compared to its average volume of 86,608. Aquinox Pharmaceuticals has a fifty-two week low of $10.68 and a fifty-two week high of $19.97.

COPYRIGHT VIOLATION WARNING: “Cantor Fitzgerald Reiterates Buy Rating for Aquinox Pharmaceuticals, Inc. (AQXP)” was originally reported by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are accessing this story on another domain, it was illegally stolen and reposted in violation of United States and international trademark and copyright legislation. The original version of this story can be accessed at https://www.thecerbatgem.com/2017/11/13/cantor-fitzgerald-reiterates-buy-rating-for-aquinox-pharmaceuticals-inc-aqxp.html.

Institutional investors and hedge funds have recently made changes to their positions in the company. Investment Centers of America Inc. acquired a new position in shares of Aquinox Pharmaceuticals during the 3rd quarter worth $175,000. Citadel Advisors LLC acquired a new position in shares of Aquinox Pharmaceuticals during the 3rd quarter worth $194,000. Archon Partners LLC increased its stake in shares of Aquinox Pharmaceuticals by 44.0% during the 2nd quarter. Archon Partners LLC now owns 18,000 shares of the company’s stock worth $253,000 after purchasing an additional 5,500 shares during the last quarter. Alps Advisors Inc. increased its stake in shares of Aquinox Pharmaceuticals by 4.7% during the 2nd quarter. Alps Advisors Inc. now owns 21,090 shares of the company’s stock worth $297,000 after purchasing an additional 939 shares during the last quarter. Finally, Bank of New York Mellon Corp increased its stake in shares of Aquinox Pharmaceuticals by 16.5% during the 2nd quarter. Bank of New York Mellon Corp now owns 23,260 shares of the company’s stock worth $327,000 after purchasing an additional 3,299 shares during the last quarter. Institutional investors own 95.16% of the company’s stock.

Aquinox Pharmaceuticals Company Profile

Aquinox Pharmaceuticals, Inc is a clinical-stage pharmaceutical company discovering and developing targeted therapeutics in disease areas of inflammation and immuno-oncology. The Company’s primary focus is anti-inflammatory product candidates targeting the Src Homology 2 (SH2)-containing inositol-5-phosphatase 1 (SHIP1) enzyme, which is a regulator of a cellular signaling pathway in immune cells, known as the phosphatidylinositol-4,5-bisphosphate 3-kinase (PI3K) pathway.

Receive News & Stock Ratings for Aquinox Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aquinox Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.